Eagle Global Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Eagle Global Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-156,897	Closed	-$2.87M	–	264
2021 Q1	$2.87M	Sell	156,897 -3,689	-2%	-$66.4K	0.21%	90
2020 Q4	$2.92M	Sell	160,586 -10,616	-6%	-$186K	0.23%	91
2020 Q3	$3.05M	Sell	171,202 -1,513	-0.9%	-$27.5K	0.27%	84
2020 Q2	$3.1M	Sell	172,715 -6,749	-4%	-$121K	0.28%	82
2020 Q1	$2.72M	Sell	179,464 -8,101	-4%	-$147K	0.28%	81
2019 Q4	$3.7M	Buy	187,565 +65,125	+53%	+$1.25M	0.19%	89
2019 Q3	$2.11M	Sell	122,440 -14,104	-10%	-$244K	0.09%	108
2019 Q2	$2.42M	Buy	136,544 +31,872	+30%	+$580K	0.1%	105
2019 Q1	$2.13M	Buy	+104,672	New	+$2.11M	0.08%	116

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eagle Global Advisors's TAK Position: Q2 2021 in Review

Eagle Global Advisors sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 156,897 shares — an estimated $2.87M sold.

Eagle Global Advisors first reported a position in TAK in Q1 2019 and held it in 9 quarters. The position peaked at $3.7M in Q4 2019. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

Eagle Global Advisors reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Eagle Global Advisors sold 156,897 Takeda Pharmaceutical shares in Q2 2021, an estimated $2.87M.
Eagle Global Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 9 quarters.
Eagle Global Advisors's Takeda Pharmaceutical position peaked at $3.7M in Q4 2019.
304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on Eagle Global Advisors's 13F filing for Q2 2021, filed 15 Jul 2021.